We read with great interest the article 'Licence to Save: a UK survey of anti-VEGF use for the eye in 2015'. 1 It is a particularly pertinent and well-timed article given the recently declared 'crisis' the NHS is experiencing. We are writing to highlight the potential influence this article may have now that the 'Getting It Right the First Time' (GIRFT; http://www.gettingitrightfirsttime.com) project will eventually extend to subspecialties such as ophthalmology. The GIRFT project was initially piloted in orthopaedics, financially supported by the NHS PCC (Primary Care Commissioning). The GIRFT project is a comprehensive review of service seeking improvement through the careful analysis of existing care pathways, patient experience, waiting times, service costs, cost commissioning, surgical targets, and outcomes, with the aim of developing a more standardized improved national service (http://www.gettingitrightfirsttime. com/downloads/GIRFT-National-Report.pdf). It will be interesting to see if this service review in ophthalmology will impact on drug licensing and our current anti-VEGF practices.
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The authors declare no conflict of interest. Ranibizumab was given to 55% (n = 31) and dexamethasone to 29% (n = 16). There was no significant difference (P = 0.7) in the follow-up periods for patients who received ranibizumab (mean 171.2 days, standard deviation (SD) 46.3) compared to dexamethasone (mean 177.9 days, SD 64.8). The number of injections was significantly different for the two drugs (Po0.001), with a mean of 3.1 (SD 0.9) for ranibizumab and 1.1 (SD 0.3) for dexamethasone. For example, for ranibizumab 55% received three injections and 29% received four injections, while for dexamethasone 88% (n = 14) received one injection. There was no significant difference (P = 0.9) in BCVA from the first injection to follow-up: mean +7.3 letters (SD 12.3) for ranibizumab and +7.8 letters (SD 8.6) for dexamethasone. Similarly, central retinal thickness changes were not significantly different (P = 0.95): − 165.5 μm (SD 218.7) for ranibizumab, and − 169.1 μm (SD 152.3) for dexamethasone. Intraocular pressurelowering topical treatment was needed in 5% following ranibizumab and 23% following dexamethasone. The visual results obtained fall short of those achieved in clinical trials and treatment patterns in our clinic are now closer to the label recommendations.
Our practice was and remains to monitor patients on ranibizumab monthly, injecting if appropriate, and for dexamethasone to review patients 6 weeks following the implant, and then at least 3 months later depending on any prior clinical responses. Thus, similar outcomes are obtainable with ranibizumab and dexamethasone, but with far fewer treatment and non-treatment visits for the latter. The article 'Benchmarks for outcome indicators in pediatric cataract surgery', in which 96% of operated children had outcomes of best corrected visual acuity ≥ 20/40, 1 is in stark contrast to what was obtained in some low and middle income countries settings. Herein, we describe the profile of the cataract blind children in special schools in Southeast Nigeria and their unmet needs. This study was done concurrently with research into trends in childhood blindness in which part of the methodology has been reported elsewhere. 2 Data regarding onset of blindness, history of cataract surgery, ocular examination, refraction, and low vision assessment were recorded on the WHO/PBL form for childhood blindness and analysed with STATA 12.1 (Statcorp, TX, USA), from which frequency tables, oddratios, and P-values were generated. Tests of significance were set at the 95% level. Out of 127 children with childhood blindness in schools for the blind, 42 had lensrelated pathologies. Figure 1 shows the categorization of children with lensrelated blindness and Table 1 shows the relevant relationship of correlates between operated and unoperated participants. There were several unmet needs in these cataract blind children. First, the presence of children in the school for the blind with unoperated cataracts is a cause for concern. In addition, the outcome of surgery was poor. Furthermore, none of the children who had undergone surgery had any evidence of intraocular lenses (IOLs) or any optical rehabilitation post surgery. One participant's vision improved from o6/60 to 6/60 in one eye after refraction. There is suggestive evidence that the odds of having surgery in ≤ 15-year-olds was almost three and a half times greater than in those 415 years. This implies that the rate of cataract surgery in children may have increased over time. However, cataract surgery is not synonymous with good vision. Existing data suggest that many cataract blind or visually impaired children in low and middle income countries have undergone previous surgery, but that their vision has remained poor. 3 Several factors affect the outcome of paediatric cataract surgery-these include delay in surgery and inadequate postoperative rehabilitation. 4 In the absence of medical records on these blind children, there were limited data on the timing of surgery and follow-up period. This was a blind-school survey;
